GLP-1 Peptide Side Effects: What Clinical Trials Have Documented

GLP-1 receptor agonists are among the most studied compounds in metabolic research. With that research comes a detailed characterization of their side effect profiles. Understanding what has been documented, how common each effect is, and how it varies by compound is essential context for any researcher working in this space.

The Most Common Side Effects: Gastrointestinal

Gastrointestinal side effects are the most consistently reported adverse events across the entire GLP-1 class. They stem from the mechanism itself: GLP-1 receptors are present in the gut, and activating them slows gastric emptying and affects gut motility. Nausea is the most common, reported by anywhere from 20 to 50 percent of participants in various trials depending on dose. Vomiting, diarrhea, and constipation follow at lower rates.

These effects are dose-dependent and most pronounced during dose escalation. For most participants in trials, gastrointestinal side effects diminish after several weeks at a stable dose. They can return when doses are increased. Importantly, nausea is one of the primary reasons participants discontinue GLP-1 compounds in trials, which affects the interpretation of completers-only efficacy data.

Serious Adverse Events: What the Data Shows

More serious adverse events have been documented across GLP-1 trials, though at lower rates. Pancreatitis has been observed in semaglutide and tirzepatide trials, though the causal relationship and rate relative to baseline risk in the study population has been debated. Gallbladder disease, including cholelithiasis (gallstones), has been reported at higher rates in GLP-1 users than in placebo groups across multiple trials, likely related to rapid weight loss affecting bile composition.

Thyroid C-cell tumors were observed in rodent studies for semaglutide, leading to a black box warning on the label. This finding has not been confirmed in human clinical data. The SELECT trial for semaglutide showed a reduction in major cardiovascular events in a population with existing cardiovascular disease and obesity, which is a positive safety signal for that population.

Muscle Mass Loss

One emerging area of concern in GLP-1 research is the composition of weight lost. Studies have shown that GLP-1-induced weight loss includes a meaningful proportion of lean muscle mass alongside fat. Some analyses suggest lean mass loss in GLP-1 trials may be higher proportionally than what is seen with diet alone. The long-term implications of this for metabolic health are being actively studied. Some researchers combine GLP-1 compounds with resistance exercise protocols to examine whether muscle loss can be mitigated.

Heart Rate Changes

Semaglutide and especially retatrutide have shown modest increases in resting heart rate in trial participants. In the retatrutide Phase 2 trial, a mean increase of approximately 2 to 4 beats per minute was observed, with higher increases at the highest doses. This is being monitored in Phase 3. The mechanism is not fully understood but may relate to glucagon receptor activation affecting cardiac function.

Injection Site Reactions

All subcutaneously injected GLP-1 compounds produce some rate of injection site reactions: redness, bruising, and transient discomfort. These are generally mild and do not typically cause discontinuation. Proper injection technique and site rotation reduce the frequency and severity of these reactions in research protocols.

What Happens to Side Effects When the Compound Is Stopped

Gastrointestinal side effects resolve quickly when dosing stops, typically within days. Any weight regained after stopping is not accompanied by a return of side effects: the side effects are pharmacological, not persistent. Heart rate changes documented during treatment also appear to normalize after discontinuation. This is covered in more depth in a dedicated post on what happens when GLP-1 compounds are discontinued.

Werner Science provides research-grade GLP-1 peptides including semaglutide, tirzepatide, and retatrutide. Browse their catalog at wernerscience.com/?ref=bwmucbwp and use code SAVE10 at checkout.